Rik J. Verheijden
YOU?
Author Swipe
View article: Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment Open
View article: AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma
AI-detected tumor-infiltrating lymphocytes for predicting outcomes in anti-PD1 based treated melanoma Open
Importance Easy and accessible biomarkers to predict response to immune checkpoint inhibition (ICI)-treated melanoma are limited. Objective To evaluate artificial intelligence (AI) detected tumor-infiltrating lymphocytes (TILs) on pretreat…
View article: Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study Open
Background The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside computed tomography (CT)-derived body composi…
View article: Gut microbiome and immune checkpoint inhibitor toxicity
Gut microbiome and immune checkpoint inhibitor toxicity Open
Gut microbiome dysbiosis signaled by higher RA of pathobionts and decrease in RA of Ruminococcaceae may predispose to severe irAEs.
View article: Checkpoint Inhibitor Effectiveness after Corticosteroids and Second-Line Immunosuppressants for Immune-Related Adverse Events in Non-Small Cell Lung Cancer
Checkpoint Inhibitor Effectiveness after Corticosteroids and Second-Line Immunosuppressants for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Open
View article: Body Composition Metrics and Immune Related Adverse Events in Advanced Melanoma: A Multicenter Cohort Study
Body Composition Metrics and Immune Related Adverse Events in Advanced Melanoma: A Multicenter Cohort Study Open
View article: Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events Open
High-dose steroids constitute the cornerstone of first-line treatment for immune-related adverse events (irAEs) associated with immune checkpoint inhibitors, but compromise antitumor immunity. A deeper understanding of irAEs and their resp…
View article: Next-generation IgA-SEQ allows for high-throughput, anaerobic, and metagenomic assessment of IgA-coated bacteria
Next-generation IgA-SEQ allows for high-throughput, anaerobic, and metagenomic assessment of IgA-coated bacteria Open
Our magnetic 96-well plate-based high-throughput next-generation IgA-SEQ technology efficiently identifies a great number of IgA-coated bacteria from fecal samples. This paves the way for analyzing large cohorts as well as novel downstream…
View article: In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients Open
View article: Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma Open
High corticosteroid peak dose and second-line immunosuppressants to treat irAEs are both associated with impaired survival. While immunosuppression is indispensable for treatment of severe irAEs, clinicians should weigh possible detrimenta…
View article: Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma Open
View article: Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study
Body composition and checkpoint inhibitor treatment outcomes in advanced melanoma: a multicenter cohort study Open
Introduction The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to add to previous evidence by investigating body mass index (BMI) alongside CT derived bo…
View article: A prediction model for response to immune checkpoint inhibition in advanced melanoma
A prediction model for response to immune checkpoint inhibition in advanced melanoma Open
Predicting who will benefit from treatment with immune checkpoint inhibition (ICI) in patients with advanced melanoma is challenging. We developed a multivariable prediction model for response to ICI, using routinely available clinical dat…
View article: BRAF/MEK inhibitor rechallenge in advanced melanoma patients
BRAF/MEK inhibitor rechallenge in advanced melanoma patients Open
Background Effectivity of BRAF(/MEK) inhibitor rechallenge has been described in prior studies. However, structured data are largely lacking. Methods Data from all advanced melanoma patients treated with BRAFi(/MEKi) rechallenge were retri…
View article: Physical activity and checkpoint inhibition: association with toxicity and survival
Physical activity and checkpoint inhibition: association with toxicity and survival Open
Background Although animal experiments suggest beneficial effects of physical activity (PA) on antitumor immunity, little is known about the effects of PA on immune checkpoint inhibitor (ICI) toxicity and effectiveness in humans. We assess…
View article: Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition Open
View article: 1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
1157P Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival Open
View article: Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis
Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor colitis Open
View article: Prognostic value of Lynch syndrome, <i>BRAF<sup>V600E</sup></i>, and <scp><i>RAS</i></scp> mutational status in <scp>dMMR</scp>/<scp>MSI‐H</scp> metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
Prognostic value of Lynch syndrome, <i>BRAF<sup>V600E</sup></i>, and <span><i>RAS</i></span> mutational status in <span>dMMR</span>/<span>MSI‐H</span> metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts Open
Background Current knowledge on prognostic biomarkers (especially BRAF V600E / RAS mutations) in metastatic colorectal cancer (mCRC) is mainly based on mCRC patients with proficient mismatch repair (pMMR) tumors. It is uncertain whether th…
View article: Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance Open
Immune checkpoint inhibitors (ICIs) have changed perspectives for patients with cancer, but come with severe immune-related adverse events (irAEs). To prevent fatality or chronicity, these irAEs are often promptly treated with high-dose im…
View article: Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor induced colitis
Highly multiplexed spatial analysis identifies tissue-resident memory T cells as drivers of ulcerative and immune checkpoint inhibitor induced colitis Open
Summary Colitis is a prevalent adverse event associated with immune checkpoint inhibitor (ICI) therapy with similarities to inflammatory bowel disease. Incomplete mechanistic understanding of ICI-colitis curtails evidence-based treatment. …
View article: Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open
Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with ov…
View article: Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open
Purpose:Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown.Experimental…
View article: Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open
Purpose:Unleashing the immune system by PD-1 and/or CTLA-4 blockade can cause severe immune-related toxicity necessitating immunosuppressive treatment. Whether immunosuppression for toxicity impacts survival is largely unknown.Experimental…
View article: Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry Open
Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with ov…
View article: Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma
Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma Open
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can b…
View article: Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition Open
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs). Mechanistic studies can aid the transition from expert-opin…
View article: Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma Open
Importance Management of checkpoint inhibitor–induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti–tumor necrosis factor on checkpoint-inhibitor effic…
View article: 365P Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts
365P Prognostic value of Lynch syndrome, BRAFV600E and RAS mutation status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of the national Dutch and French cohorts Open
View article: Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Frailty and checkpoint inhibitor toxicity in older patients with melanoma Open
Background Immune checkpoint inhibitors (ICIs) can cause immune‐related adverse events (irAEs) that range from mild to life‐threatening. Age itself does not seem to be a predictor for the occurrence of irAEs. It is unknown whether frailty …